What's trending

5 most popular innovation stories in Houston this week

Cyvia Wolff's $13 million donation from her foundation to the University of Houston entrepreneurship program was among this week's top stories in Houston innovation. Photo via UH.edu

Editor's note: Among this week's top stories were four powerful female Houston innovators, a generous donation to the University of Houston, and more. Scroll through to see what Houston innovation stories trended this week.

3 Houston female innovators to know this week

This week's set of who's who include a startup founder trying to change the world, a passionate PhD with a story of failure to tell, and a biomedical engineer enhancing health tech in Houston. Courtesy photos

Another set of female innovation leaders are making headlines as we move into another week of innovators to know.

This week's set of who's who include a startup founder trying to change the world, a passionate PhD with a story of failure to tell, and a biomedical engineer enhancing health tech in Houston. Continue reading.

University of Houston receives historic $13M gift for its entrepreneurship program

UH has maintained its spot on the top 100 global universities for number of patents issued. Photo courtesy of University of Houston

University of Houston's C.T. Bauer College of Business has received its second largest donation to benefit its entrepreneurship program.

The Cyvia and Melvyn Wolff Center for Entrepreneurship, which was recently ranked the top undergraduate entrepreneurship program in the country, received the $13 million gift from its namesake foundation — The Cyvia and Melvyn Wolff Family Foundation — and the state of Texas is expected to match an additional $2 million, bringing the total impact to $15 million.

"Our family is deeply committed to the ideals of entrepreneurship," says Cyvia Wolff in a news release. "Our business personified everything that it means to be an entrepreneur. The skills, the thinking, the mindset are fundamental to success for business leaders today and in the future. On behalf of my late husband, we are truly honored to ensure the entrepreneurial legacy not only endures but remains accessible for students. We are truly honored to be part of this program and university." Continue reading.

Growing Houston startup is digitizing the dining experience

roovy

Houston-based Roovy Technologies has created a mobile app where people can control their dining experience completely from their phones. Photo via roovy.io

Imagine going into a popular restaurant, sitting down at an open table and controlling the entire dining experience from a smartphone. That's food, drinks, and even dessert all ordered and paid for on a phone.

Prolific Houston-area restaurateur Ken Bridge had the vision to converge dining with technology by creating a digital solution to combat chronic wait times in restaurants. That vision became the Roovy Technologies mobile app, a platform designed to create the ultimate convenience for gastronauts everywhere. Continue reading.

Top 5 Houston health tech stories of 2019

Houston, home to the largest medical center in the world, was ranked the second in the nation for emerging life science clusters. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Editor's note: As 2019 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. Within the health category, top stories included new details from the Texas Medical Center's ongoing TMC3 project, health tech and medical device startups in Houston, and more. Continue reading.

Houston Methodist executive to lead the hospital into the future of health care

Roberta Schwartz is leading the innovation initiative at Houston Methodist. Courtesy of Houston Methodist

It may come as no surprise to anyone who's met Roberta Schwartz that she's a self starter. Schwartz, who is the executive vice president and chief innovation officer for Houston Methodist, was among the group that organized to create what is now the Center for Innovation within the hospital system.

But one of her earlier moments of innovation leadership came when she was diagnosed with cancer at a young age. She co-founded the Young Survival Coalition to help connect young breast cancer patients like herself.

"I was 27 when I was unexpectedly diagnosed with breast cancer — I have no family history, no cancer in the family. It certainly was a shock to my system," Schwartz says on this week's episode of the Houston Innovators Podcast. "Once I was diagnosed, and through some of the original surgery and care I had to do, I knew that I wanted to reach out and find a larger community of young women."Continue reading.

Trending News

 
 

Promoted

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Trending News

 
 

Promoted